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Squamous cell carcinoma of the head and neck (SCC-HN) has
consistent deletions at a number of chromosomal positions
including a high frequency at 10q (Bockmuhl et al, 2000). The
tumour suppressor gene PTEN (phosphatase and tensin homo-
logue located on chromosome 10) at 10q23 is mutated in a variety
of tumour types and in the germline of some individuals with
Cowdens disease who are predisposed to cancer (Marsh et al,
1999). PTEN, also known as MMAC1 (mutated in multiple
advanced cancers) and Tep1, has been reported to be mutated and
deleted in a variety of carcinomas and glioblastomas, particularly
advanced and metastatic cases (Ali et al, 1999). The gene encodes
a dual specificity phosphatase a key biological function of which
is to remove phosphate residues from PIP3 (Maehama and Dixon,
1999). The lipid phosphatase activity of PTEN thus decreases the
abundance of a central constituent in a positive cell proliferation
pathway, resulting in negative regulation of cell division (Vasquez
and Sellers, 2000). Therefore loss and mutation of the gene
leading to inactive PTEN protein would provide an obvious
growth advantage. 
Conflicting data have so far been published on the role of
PTEN loss in SCC-HN. In one study of aerodigestive SCCs, 41%
of cases had PTEN loss of heterozygosity (LOH) with a quarter
of these having mutation of the second allele or homozygous 
deletion (Okami et al, 1998). Shao et al (1998) found 6 LOHs 
and 3 mutations in 19 SCC-HN whereas in another analysis of 21
HN SCCs no PTEN loss or mutation was found (Kubo et al,
1999). It is also possible that the p110a subunit of P13 kinase
gene itself is over-expressed or amplified in SSC-HN, as its chro-
mosomal location, 3q26.3, is often over-represented in this
tumour type (Speicher et al, 1995) and the p110a subunit
of P13K is over-represented and overexpressed in ovarian
(Shayesteh et al, 1999) and cervical tumours (Ma et al, 2000).
Thus the P13 kinase pathway can be upregulated by alternative
mechanisms. 
Therefore PTEN and its associated pathways were investigated
to establish any involvement in our panel of SCC-HN cell lines,
which are more amenable to biochemical analysis than tumour
material. Loss of heterozygosity, allele mutations and the presence
of a functional gene product were assessed in 19 independent
carcinoma lines and fibroblast lines from the same individual,
where available. Lack of MXI-1 involvement had already been
established (unpublished results). Although over a third of our
lines had LOH of one PTEN allele there were no mutations in the
second allele. Furthermore PTEN and phospho Akt protein levels
have been assessed and along with an estimation of the PTEN lipid
phosphatase activity these were all shown to be normal. These
results suggest that perturbation of the P13 kinase pathway is
uncommon in SCC-HN. 
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Summary The human tumour suppressor gene PTEN located at 10q23 is mutated in a variety of tumour types particularly metastatic cases
and in the germline of some individuals with Cowdens cancer predisposition syndrome. We have assessed the status of PTEN and
associated pathways in cell lines derived from 19 squamous cell carcinomas of the head and neck. Loss of heterozygosity is evident at, or
close to the PTEN gene in 5 cases, however there were no mutations in the remaining alleles. Furthermore by Western analysis PTEN protein
levels are normal in all of these SCC-HN tumours and cell lines. To assess the possibility that PTEN may be inactivated by another
mechanism, we characterized lipid phosphatase levels and from a specific PIP3 biochemical assay it is clear that PTEN is functionally active
in all 19 human SCCs. Our data strongly suggest the possibility that a tumour suppressor gene associated with development of SCC-HN,
other than PTEN, is located in this chromosomal region. This gene does not appear to be MXI-1, which has been implicated in some other
human tumour types. PTEN is an important negative regulator of PI3Kinase, of which subunit alpha is frequently amplified in SCC-HN. To
examine the possibility that PI3K is upregulated by amplification in this tumour set we assessed the phosphorylation status of Akt, a
downstream target of PI3K. In all cases there is no detectable increase in Akt phosphorylation. Therefore there is no detectable defect in the
PI3K pathway in SCC-HN suggesting that the reason for 3q26.3 over-representation may be due to genes other than PI3K110a. © 2001
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Cell lines 
All the cell lines were cultured using Swiss 3T3 feeders in DMEM
media supplemented with 10% FBS and 0.4 mg ml–1 hydrocorti-
sone. The SCC-HN lines are named SCC or BICR (B) and were
derived as described previously in Rheinwald and Beckett (1981)
and Edington et al (1995) respectively. Control lines included
normal keratinocytes (HEK), SV40 transformed HEK cells and a
PTEN negative melanoma cell line SK Mel 23 (Yamashita et al,
1999). Matched fibroblasts were derived from the same patients
with the original tumours (F) i.e. 6B and 6F, for example, are
tumour and control lines from the same individual. 
LOH analysis by microsatellite PCR 
Microsatellite PCR reactions contained 1.5 mM MgCl2, 0.2 mM
each dNTP, 0.2 mM each primer, 40 ng template DNA, 0.5 U Taq
polymerase (Promega), and 1 ´ Taq buffer (Promega) in a 12.5 ml
volume. For these reactions, a 5 minute denaturation step at 95˚C
was followed by 35 cycles of 30 seconds at 95˚C, 75 seconds at
52˚C and 30 seconds at 72˚C. This was followed by a final exten-
sion step of 5 minutes at 72˚C. 
Locus Primer Sequence 
D10S185 6a: 5¢-TCCTATGCTTTCATTTGCCA-3¢
6m: 5¢-CAAGACACACGATGTGCCAG-3¢
D10S2491 265AF: 5¢-GTTAGATAGAGTACCTGCACTC-3¢
(PTEN) 265AR: 5¢-TTATAAGGACTGAGTGAGGGA-3¢
D10S192 094tcaa: 5¢TTATACTAGGAAACAAGGCTTACC-3¢
094tcab: 5¢-GGGCTTAAATGAATGACAC-3¢
MXI-1 PS1 MXI-1.R: 5¢-TTAAATACAGGTCCTCTGACCC- 3¢
MXI1.F: 5¢-GGTTACTCCCGTGCCAGTGT-3¢
D10S587 6816: 5¢-CCCAGATTCATGGCTTTC-3¢
6817: 5¢-TTCTGCTGACACACGGGC-3¢
D10S222 3017: 5¢-TGGAAACCTACCGAATGGA-3¢
3018: 5¢-TCTAACTGTGGATTGAAGCGAC-3¢
Denaturing polycrylamide gel electrophoresis 
For resolution of microsatellite markers, 6% denaturing acrylamide
gels (6% acrylamide 1 ´ TBE, 7 M urea) were used. Following the
addition of 1/2 volume loading dye (95% formamide, 20 mM EDTA,
0.25% xylene cyanol, 0.25% bromophenol blue), the samples were
heat denatured at 94˚C for 5 min prior to loading. The Protean II
system (Biorad) was used, and the gels electrophoresed at 300 V for
at least 4 hours. 
Visualization was by silver staining. 
PCR and sequencing of PTEN Exons 
Each exon was amplified individually from genomic DNA using
intron specific primer sequences (Reisinger et al, 1997). PCR reac-
tions contained 1.5 mM MgCl2, 0.2 mM each dNTP, 1 mM each
primer, 50 ng template DNA, 1 U Taq polymerase (Promega), and
1 ´ Taq buffer (Promega) in a 25 m1 volume. Reaction conditions
were as follows: 95˚C for 5 min, then 7 cycles of 30 s at 95˚C, 30 s
at 55˚C, decreased by 1˚ per cycle, and 1 min at 72˚C. This was
followed by 30 cycles of 1 min each at 95˚C, 48˚C and 72˚C
respectively and a final 6 min extension at 72˚C. 
Each product was then electrophoresed on 1% agarose, visual-
ized by ethidium bromide staining, and the bands excised and puri-
fied using the Geneclean II kit (Bio 101). 
50 ng of each template was initially sequenced using the
Sequenase PCR product Sequencing kit (Amersham). Sequence
was confirmed by cloning each product into pGEM-T Easy vector
(Promega) and sequencing in both directions using M13 Universal
and Reverse primers with the Sequenase V2.0 sequencing kit
(Amersham). 
Western blotting 
1 ´ 106 cells were lysed in 100ml RIPA buffer (1 ´ PBS, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing
5 mgm l –1 aprotonin, 5 mgm l –1 leupeptin, 5 mgm l –1 pepstatin A, 1
mM benzamidine and 50 mgm l –1 PMSF. Lysates were left on ice
for 20 min, then centrifuged at 13 000 rpm for 15 min. Cleared
supernatants were transferred to fresh microfuge tubes, and the
protein concentration of each determined by the Bradford Assay. 
30 mg each whole cell extract was mixed with an equal volume
of sample buffer (250 mM Tris, 20 mM DTT, 2% SDS, 0.01%
Bromophenol blue, 10% glycerol) and denatured at 95˚C for 5 min,
prior to separation by discontinuous SDS-PAGE on a 10% gel.
Following electrophoresis, proteins were transferred onto nitrocel-
lulose, and blocked in 1 ´ TBS (10 mM Tris, pH 8, 150 mM NaCl)
containing 5% skimmed-milk powder for at least one hour. Primary
antibody was added at the appropriate dilution in TBST (1 ´ TBS,
0.1% Tween 20) containing 0.5% milk, and incubated for an hour
with shaking. Blots were washed 4 ´ 5 min in 1 ´ TBST prior to
addition of the relevant HRP-conjugated secondary antibody (see
below for antibody details) diluted in 1 ´ TBST, 0.5% milk.
Incubation for one hour at room temperature was followed by 4
washes in TBST with a final wash in TBS. Detection of bound anti-
body was achieved using Luminol Reagent (Santa-Cruz) and expo-
sure to Hyperfilm ECL (Amersham). 
Blots were stripped in 0.2 M Glycine, pH 2.6, 0.1% SDS for one
hour at room temperature, washed several times in TBST then re-
blocked in TBS/5% milk for an hour before re-probing with a
different primary antibody. 
Antibody Dilution Secondary antibody 
PTEN A2B1  1/750 Goat anti-mouse (Sigma) 
(Santa-Cruz) 1/5000
ERK2 (Transduction  1/2000 Goat anti-mouse (Sigma) 
Labs) 1/5000
PhosphoSer473 AKT  1/1000 Goat anti-rabbit (Sigma) 
(New 1/5000 England 
Biolabs)
AKT (New England  1/1000 Goat anti-rabbit (Sigma) 
Biolabs) 1/5000
PIP3 lipid phosphatase assays 
Whole cell extracts were prepared as described above. 1 mg PTEN
A2B1 antibody (Santa-Cruz) was added to each extract and incu-
bated on a shaking platform for 1 hour at 4˚C. 20 ml Protein G
PLUS-Agarose (Santa- Cruz) was added and left for a further hour
with shaking. Immunoprecipitates were pelleted by centrifugation
at 4000 rpm and washed twice in RIPA buffer and twice in 10 mM
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Tris pH 8, 50 mM sodium chloride, each time by resuspension in
wash buffer then centrifugation as above. Immune complexes were
resuspended in enzyme reaction buffer without substrate (50 mM
Tris pH 8, 50 mM sodium chloride, 10 mM DTT, 10 mM magne-
sium chloride). This immunoprecipitated PTEN was added to
prewarmed reaction buffer (50 mM Tris pH 8, 50 mM sodium
chloride, 10 mM DTT, 10 mM magnesium chloride, 10 mM L-
a-phosphatidylinositol-3, 4, 5-triphosphate (Calbiochem)), in a 50 ml
volume. Reactions were incubated for 30 min at 37˚C, then termi-
nated by the addition of 100 ml BIOMOL Green reagent (BIOMOL).
The amount of phosphate present was determined by reading the
absorbance of the samples at 630 nm following incubation at room
temperature for 20 min to allow colour development. Phosphate
concentrations were estimated, in triplicate experiments, by compar-
ison to phosphate standards diluted in enzyme reaction buffer. 
RESULTS 
Detection of loss of heterozygosity within the PTEN
locus 
To determine whether any chromosomal loss had occurred at the
PTEN locus in our panel of 19 SCC-HNs, microsatellite analysis
was carried out using 6 primer pairs within the 10q23–26 locus.
The analysis was performed by PCR on DNA from the tumour cell
lines and direct comparisons made with matched fibroblast
controls derived from the same patient, where these were avail-
able. The results of this analysis clearly revealed LOH in BICR
cases 3, 6, 31, 78 and 82 at or adjacent to the PTEN marker
D10S491 and these are indicated by asterisks with 3 markers illus-
trated in panels A, B and C in Figure 1. Two cases, BICR 63 and
68, had clear retention of heterozygosity as illustrated in Figure 1
and a further 6 cases were non-informative possibly due to
homozygosity at this marker. Microsatellites from the PTEN
marker and 5 other markers at this chromosomal locus were used
to determine LOH status in this region as presented in Table 1. The
boundaries of potential loss are outlined in bold and in BICR3, 6,
31 and 82 this loss includes the PTEN marker (Table 1). 
Screening for mutation in the PTEN second allele
where evidence suggests loss of the first 
Loss of DNA in the vicinity of the PTEN gene suggests the pres-
ence of a tumour suppressor gene in this region, if PTEN was
the candidate then it would be accompanied by inactivation of
the second allele. With PTEN there are technical difficulties in
searching for second allele mutations due to the presence of a
highly conserved pseudogene which directly interferes with the
PCR process when exon specific primers are used, therefore
intron specific primers have been designed (Risinger et al,
1997). These primers allowed specific exon amplification from
the functional gene. Sequencing of the products from all 9 exons
revealed a complete lack of any somatic mutations in our LOH
tumour DNAs from cases BICR 3, 6, 31, 78 and 82. 
Assessment of PTEN and phosphoAkt protein levels by
Western analysis 
Methylation, rather than mutation, can be a mechanism of PTEN
inactivation (Whang et al, 1998) and may have explained the lack
of second allele mutations. To rule out the possibility of another
gene inactivation mechanism initially PTEN protein levels were
determined by Western analysis. The recent availability of a 
C-terminal antibody to PTEN allowed clear characterization of
protein levels in this SCC-HN series. All 19 lines were analysed by
Western blotting, 17 of these are illustrated in Figure 2 with PTEN
in the upper panel. Inclusion of SKMe123 (Right hand lane, 
Figure 2), the well characterized PTEN negative, melanoma cell
line, as a control allowed us to contrast the abundant PTEN levels
in our tumour set. These significant levels of PTEN were also found 
in keratinocyte control line HEK and SV40 transformed
keratinocytes and correlated inversely with the abundance of
phospho Akt (Figure 2, panel below PTEN). Again in contrast to
this in the SKMe123 line phospho Akt levels were high (right hand
lane same panel). The presence of phospho Akt is a clear indicator
of an active P13 Kinase pathway, which is only found in the
absence of PTEN. As shown total Akt levels are uniform
throughout and densitometry verifies this visual analysis. Bradfords
assays were used to load an accurate 30 ug per lane. As a loading
control we used the ERK2 (Cobb and Goldsmith, 1995), antibody
and this clearly illustrates the presence of protein equivalents in
every lane in a reproducible manner (bottom panel Figure 2). 
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Figure 1 Microsatellite analysis of 14 tumour cases (B and SCC) and
matched controls where available (F) illustrating LOH in 5 of these. Three
markers illustrated are D10S 185 (A), the PTEN marker D10S2491 (B) and
marker D10S192 (C). Allele loss is indicated by an asterisk beside the
remaining allele 
Locus
D10S185 D10S491 D10S491 D10S491 PS1 D10S491
Tumour name (PTEN) (MXI-1
BICR 3
BICR 6
BICR 19
BICR 31
BICR 63
BICR 68
BICR 78
BICR 82
KEY:
Loss of heterozygosity        ; Retention of heyerozygosity        ;
Non informative         ; Tumour names are listed down the left hand side
and microsatellite markers along the top with potential regions of loss
boxed in bold.
Table 1 LOH data for HN SCC tumour setPTEN in squamous cell carcinomas 1633
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PIP3 lipid phosphatase activity in this tumour series 
Having confirmed that PTEN protein was present in our head and
neck squamous cell carcinoma lines we wished to determine
whether this protein was indeed functionally active. To do this we
carried out a colorimetric, PIP3-specific, lipid phosphatase assay.
Included in this assay was the PTEN-negative SKMe123 line and
normal human keratinocytes as negative and positive controls
respectively. The assays were optimized using time course experi-
ments and carried out in triplicate. Immunoprecipitated PTEN
protein was assayed and found to be active in all SCC and BICR
lines examined with a range of phosphatase activity reproducibly
represented by 280–385 pmoles of phosphate released (Figure 3
and Table 2). Basal levels of PTEN activity were detected in the
SKMe123 line, the mock immunoprecipitation and the control
with buffer and substrate alone (top 3 bars in Figure 3). 
DISCUSSION 
Chromosomal loss in cancers is very common with consistent
patterns giving strong clues to tumour suppressor gene location.
Table 2 Statistical analysis of phosphate release in PTEN assay 
Cell line Mean released phosphate (pmol) SEM (+/–) P
HEK 373 14.814 1.000 
BICR3 357 8.819 0.400 
SCC4 322 4.410 0.063 
BICR6 345 13.229 0.228 
SCC9 330 7.638 0.081 
BICR10 352 6.667 0.281 
SCC12 362 22.048 0.686 
SCC13 355 10.408 0.375 
SCC15 320 2.887 0.064 
BICR16 358 9.280 0.448 
BICR18 332 11.667 0.095 
BICR19 350 8.660 0.261 
BICR22 340 5.000 0.143 
SCC25 367 11.667 0.742 
BICR31 327 4.410 0.077 
BICR56 333 6.667 0.097 
BICR68 350 10.000 0.271 
BICR78 333 6.667 0.097 
BICR82 348 11.667 0.259 
DOK 382 21.279 0.766 
SV40HEK 397 8.819 0.262 
SK Mel 23 27 3.333 0.001 
Shown is the mean of the phosphate released from PIP3 by
immunoprecipitated PTEN from each cell line in 3 independent experiments
and the standard error of the mean (SEM) in each case. P is a measure of
the probability that the difference in phosphate released between each cell
line and HEK cells occurred by chance, calculated using the t-test method.
Statistical significance is indicated by P < 0.05. 
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Figure 2 Western analysis of a sample of 17 of our tumour lines and 4
controls with cell lines labelled along the top. The antibodies are indicated
beside the appropriate panel down the left hand side with the protein size on
the RHS 
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Figure 3 Graphical representation of phosphatase assay data. Each bar is
labelled with the representative assay contents and the Y axis indicates
picomoles of phosphate released in the PIP3 colorimetric assay with
immunoprecipitated PTEN protein 1634 J Snaddon et al
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Loss of 10q in SCC-HN has a controversial history which led us to
approach the problem using both DNA marker loss complemented
with biochemical analysis of the PTEN gene product and members
of the associated P13 Kinase signal transduction pathway. Loss of
the chromosomal region including PTEN occurs in 26% of this
tumour series which provides a strong indication that there is a
tumour suppressor gene at this site. In this subset of lines all 9
exons in the remaining PTEN allele were sequenced and shown to
be the same as normal. The lack of mutation in the coding exons of
the second allele of PTEN suggests that this gene may not be the
deletion target in this locus. However other mechanisms of gene
inactivation are possible (Whang et al, 1998) and we eliminated
these by detection of significant PTEN protein levels and specific
lipid phosphatase activity. LOH is also seen within the MXI-1
gene in line BICR 31 however no mutation was discovered in the
second allele (unpublished results) suggesting a lack of direct
involvement of this gene. 
Since relatively similar PTEN lipid phosphatase activities
were found in all SCC tumour and normal cell lines and no
significantly different levels were found in corresponding situa-
tions in which LOH was recorded, PTEN gene dosage does not
appear to play a role in the immortalization of these cells. This
highlights the importance of the specific functional assay, where
several years ago mutations may have been artefactual or
confused with the pseudogene (Rhei et al, 1997) our approach
answers directly whether PTEN is inactivated or decreased in
activity. 
Protein phosphatases can antagonise or modulate the signals
mediated by protein kinases. PTEN negatively controls the PI3
kinase signalling pathway and results in regulation of cell growth
and survival. The inverse correlation between PTEN and Phospho
Akt levels is well recognized in normal cells (Vasquez and Sellers,
2000), since this is a member of the signal transduction pathway
switched off by functional PTEN. A lack of phospho Akt allowed
us to confirm the presence of functional PTEN in our tumour lines.
Also in the control, SK Mel 23, PTEN is inactive and phospho Akt
levels are correspondingly high. Interestingly the low phospho 
Akt levels in our SCC-HN lines also suggests low PI3 Kinase
levels despite the observation that the p110a subunit maps to the
SCC-HN amplicon at 3q26.3. However, the lack of significantly
increased Akt phosporylation suggests that PI3 kinase is not
amplified in these tumours. 
PTEN may affect tumour invasion and metastasis (Gas-
parotto et al, 1999) and also replicative senescence (Tresini et al,
1999). All the keratinocyte cultures studied are immortal but our
results showing mainly low levels of Akt phosporylation, do not
support a general role for PI3 kinase upregulation in the immor-
talization of this type. A pattern that is now emerging, and is
supported by our data, suggests that PTEN loss is infrequent in
SCC-HN (Chen et al, 2000) and is more commonly associated
with metastatic SCCs at low frequency and as our tumour series
contains mainly primary or recurrent and only one metastatic
tumour (BICR 22) this could explain the lack of PTEN involve-
ment. 
In conclusion it appears likely from our data that another
tumour suppressor gene located in close proximity to MXI-1 and
PTEN is lost in a high proportion of head and neck squamous cell
carcinomas. Alternatively, the loss of 10q23 may be co-selected
with other chromosome losses in SCC-HN progression. The
future characterisation of other genes near to PTEN should
resolve this issue. 
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